The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZNTL | -66.33% | -96.72% | -49.46% | -94% |
| S&P | +13.19% | +87.83% | +13.42% | +171% |
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.16M | 50.2% |
| Gross Margin | 98.82% | 0.0% |
| Market Cap | $108.92M | -58.4% |
| Market Cap / Employee | $0.66M | 0.0% |
| Employees | 166 | -1.2% |
| Net Income | -$26.69M | 33.5% |
| EBITDA | -$33.57M | 34.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $39.07M | -5.4% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $36.71M | -9.3% |
| Short Term Debt | $3.75M | 33.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.39% | -3.8% |
| Return On Invested Capital | -46.24% | 5.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$26.96M | 38.8% |
| Operating Free Cash Flow | -$26.96M | 38.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.61 | 0.34 | 0.28 | 0.40 | -41.99% |
| Price to Sales | 3.20 | 4.24 | 3.11 | 4.05 | -37.15% |
| Price to Tangible Book Value | 0.61 | 0.34 | 0.28 | 0.40 | -42.55% |
| Enterprise Value to EBITDA | 2.46 | 4.94 | 4.98 | 3.91 | 131.64% |
| Return on Equity | -42.8% | -59.5% | -49.5% | -49.2% | 14.68% |
| Total Debt | $42.65M | $38.65M | $41.32M | $40.46M | -6.49% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
